GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Enliven Therapeutics ELVN · USD

Health Care · US listing · 🇺🇸 United States

Compare

51.55

+4.29%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

21 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 7Strong buy
  • 13Buy
  • 1Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Average target 76.00

Low
65.00
Average
76.00
Median
78.00
High
82.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$10,000$5,000$7,143$38.7m$271.0m
Revenue, highest$10,000$5,000$7,143$38.7m$271.0m
Revenue, lowest$10,000$5,000$7,143$38.7m$271.0m
Earnings per share-1.86-2.27-2.83-3.14-1.46
Earnings per share, highest-1.43-1.95-2.26-3.14-1.46
Earnings per share, lowest-2.13-2.46-3.30-3.14-1.46
Analysts510944

Earnings against forecasts

Earnings per share by fiscal quarter

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Forecast-0.39-0.44-0.42-0.44-0.54-0.51-0.53-0.51
Reported-0.49-0.38-0.48-0.32-0.49-0.57-0.46-0.48
Difference-26.5%+13.6%-14.3%+27.7%+10.0%-10.7%+13.5%+5.3%

Rating changes

Latest broker notes

  • MizuhoOutperform
  • StifelBuy
  • GuggenheimBuy
  • Goldman SachsBuy
  • Goldman SachsBuy
  • HC Wainwright & Co.Buy
  • StifelBuy
  • Jones TradingBuy
  • MizuhoOutperform
  • Goldman SachsBuy
  • HC Wainwright & Co.Buy
  • MizuhoOutperform

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

2 / 10

Revenue growth 0.0% a year over 10 years. Return on equity -22.6%.

Model fair value

41.77

From earnings —, from revenue 41.77.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.